Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-depende...

por Kefford, Richard, Sullivan, Ryan J, Miller, Wilson H, Elez, Elena M, Tan, Daniel, Kim, Kevin B, Long, Georgina V, Flaherty, Keith T, Tai, David, Stutvoet, Simone, Maacke, Heiko, Whiley, Matt, Parseval, Laure Moutouh-de, Tabernero, Josep
Publicado 2014